CEO: Cosmo Fielding-Mellen

Visit Website

AtaiBeckley is developing psychedelic drug programs to develop treatments for various psychiatric conditions, such as treatment-resistant depression, addiction, as well as for a rare disease called SUNHA.

In addition to the long term consequences of current treatment options, innovation has slowed in the area of traditional anti-depressants. AtaiBeckley’s leading compound, 5-MeO-DMT,  allows patients to treat their depression and symptoms with promising psychedelic-assisted psychotherapy.

With their decades-long extensive history in research and advocacy, AtaiBeckley is well-positioned to introduce psychedelic therapeutics as pharmacological interventions.